Dennis Cho Sells 412 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 412 shares of Twist Bioscience stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $122.62, for a total transaction of $50,519.44. Following the completion of the transaction, the insider owned 73,651 shares in the company, valued at approximately $9,031,085.62. This represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Wednesday, June 24th, Dennis Cho sold 14,205 shares of Twist Bioscience stock. The stock was sold at an average price of $89.75, for a total transaction of $1,274,898.75.
• On Monday, June 22nd, Dennis Cho sold 346 shares of Twist Bioscience stock. The stock was sold at an average price of $87.32, for a total value of $30,212.72.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $127.22 on Friday. The firm has a market cap of $7.98 billion, a P/E ratio of -57.31 and a beta of 2.22. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $155.44. The business’s 50-day moving average price is $113.51 and its 200 day moving average price is $79.33. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. During the same period in the prior year, the company earned $0.33 earnings per share. The firm’s revenue was up 23.2% on a year-over-year basis. On average, equities research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Institutional Trading of Twist Bioscience

A number of institutional investors have recently modified their holdings of TWST. E. Ohman J or Asset Management AB acquired a new stake in Twist Bioscience in the second quarter valued at $853,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Twist Bioscience during the 1st quarter worth $22,563,000. Bank of America Corp DE grew its stake in shares of Twist Bioscience by 46.3% during the 1st quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock worth $27,764,000 after purchasing an additional 184,907 shares during the period. Deutsche Bank AG purchased a new position in shares of Twist Bioscience in the 2nd quarter valued at about $9,265,000. Finally, William Blair Investment Management LLC purchased a new position in shares of Twist Bioscience in the 2nd quarter valued at about $223,722,000.

Analyst Upgrades and Downgrades

TWST has been the subject of several recent research reports. UBS Group initiated coverage on Twist Bioscience in a report on Wednesday. They set a “neutral” rating and a $144.00 price target for the company. Guggenheim reissued a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 24th. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Evercore cut shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price for the company. in a research note on Monday, July 6th. Finally, Leerink Partners set a $110.00 target price on shares of Twist Bioscience in a report on Thursday, July 16th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $98.45.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.